HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Pits 5% Minoxidil Rogaine For Women Against ‘Cosmetic, Quick Fixes’

This article was originally published in The Rose Sheet

Executive Summary

Firm’s McNeil-PPC subsidiary has patent exclusivity for Women’s Rogaine with the higher concentration of minoxidil through February 2017, tightening its grip on a market that cosmetics firms have struggled to penetrate effectively in the United States. According to a brand consultant and dermatologist, the new Rogaine offering actually helps regrow hair rather than merely “masking” the issue.

You may also be interested in...



Church & Dwight's Hair-Building Toppik Line Sets E-Commerce Bar

CEO Matthew Farrell says just 1% to 3% of C&D's sales currently are online, but the firm is learning new tricks from its recently acquired Toppik Hair Building Fibers brand, which generates around a third of its sales through e-commerce platforms. Meanwhile, the "serial acquirer" has an eye peeled for new category opportunities.

Consent Decree Tempers J&J Consumer Outlook Even As Remediation Ends

Skin-care and OTC product sales helped propel J&J’s consumer business in the fiscal 2015 first quarter, but currency headwinds dragged on results. CFO Dominic Caruso says the firm is stocking shelves more consistently with previously recalled OTCs, but FDA still needs to sign off on J&J’s remediation work before it returns to full manufacturing capacity, and the agency will monitor the company for a further five years under a 2011 consent decree.

P&G’s NIOXIN Shows How To Address Hair Loss Without An FDA Warning

With FDA scrutinizing the marketplace for cosmetics promoted as drugs, and a clear cautionary statement from the agency about topical products marketed as hair growers or hair-loss preventers, beauty firms have little choice but to incorporate approved OTC drug ingredients in such products. P&G’s professional hair-care brand NIOXIN has done just that with its new Advanced Thinning range featuring minoxidil.

Related Content

Related Companies

UsernamePublicRestriction

Register

RS019291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel